CA-ALKIRA,-INC.
Network Cloud pioneer Alkira® today announced a close collaboration with the Microsoft for Startups program, a select group of emerging businesses hand-picked by Microsoft for the benefits they offer to Microsoft Azure customers in their journey to the cloud. The select start-ups receive growth partnership and ecosystem support from Microsoft including access to technical, sales and marketing opportunities and leadership. Alkira also announced that the Alkira Cloud Services Exchange (CSX) – the core of the company’s Network Cloud platform – is now available on the Azure Marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005521/en/
The Alkira Network Cloud platform which reduces the time, cost and complexity of connectivity cloud environments, provides Azure customers with increased performance, manageability and security when deploying Windows workloads in the Azure cloud. Microsoft Azure customers can access Alkira’s solution in Azure, or in a multi-cloud network alongside other best-of-breed products in the Azure Marketplace.
Benefitting from the underlying power of Azure, Alkira CSX is delivered as a secure cloud networking infrastructure as-a-service that dynamically scales according to customers’ needs and reduces the time taken to deploy cloud networks from months to minutes.
Amir Khan, Chief Executive Officer and Founder of Alkira, said: “The time, cost and complexity of building networks in the cloud with end-to-end security and management visibility are major challenges holding back digital transformation. Our service was developed to help businesses overcome the trade-offs, complexity and long lead times associated with cloud networking. The Alkira Network Cloud platform accelerates the deployment and simplifies the management of cloud workloads, leaving customers free to focus on the objectives of their business. We’re excited to be deepening our relationship with Microsoft through the Microsoft for Startups program and to be able to offer those benefits to the growing number of organizations seeking transformational solutions from the Azure Marketplace.”
Jeff Ma, General Manager of Microsoft for Startups, commented: “Our start-up program gives new businesses access to the incredible resources of Microsoft and helps to bring the benefits of exciting new technologies like Alkira’s Network Cloud platform to Microsoft’s Azure customers. Alkira’s platform provides a powerful and flexible set of capabilities to leverage the power of Azure to deploy fully featured cloud networks.”
Mamoon Hamid, Partner at Kleiner Perkins added: “It’s time for the network to join the cloud era, and Alkira’s Cloud Networking Infrastructure as-a-Service provides customers a secure, simplified path to the Microsoft Azure cloud. Microsoft is progressively offering companies like Alkira the opportunity to help Azure customers on their cloud journey, and we're already seeing it unlock value for everyone involved."
Brad Casemore, Research Vice President, Datacenter Networks at IDC said: “IDC finds that enterprises are gaining greater appreciation of how modern infrastructure can support strategic cloud objectives such as business agility, application experience, robust security. That said, while enterprise architects want to help their organizations achieve greater business agility through the migration of workloads to cloud, they also want to ensure that the transition doesn’t entail compromises to operational control and management. Alkira’s Network Cloud platform addresses these requirements by helping organizations and their architects reconcile the business benefits of cloud with the need for effective control.”
Microsoft customers who access Alkira’s Network Cloud through Azure Marketplace benefit from reduced procurement overheads, simplified billing and quicker deployment, as well as the assurance of Microsoft certification.
For more information:
- Read Amir Khan’s blog on teaming with Microsoft
- Download an Alkira in Azure Cloud white paper
About Alkira
Alkira® developed the Network Cloud which enables Enterprises to build and deploy a global unified Cloud Network Infrastructure as-a-Service (CNaaS) that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira Cloud Services Exchange™ (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of Integrated Solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet
Alkira® is a registered trademark and Alkira Cloud Services Exchange™ is a trademark of Alkira, Inc. All other marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005521/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom